Table 2 Treatment details for two groups
Treatment | Open surgery (n=68) | MIS (n=61) | P value |
|---|---|---|---|
Technique | Â | Â | 0.313 |
 IMRT | 52 (76.5) | 51 (83.6) |  |
 3D-CRT | 16 (23.5) | 10 (16.4) |  |
Postoperative treatment | Â | Â | 0.959 |
 RT alone | 8 (11.8) | 7 (11.5) |  |
 RT+CT | 60 (88.2) | 54 (88.5) |  |
Intracavitary radiotherapy | 7 (10.4) | 3 (5.0) | 0.332 |
Chemotherapy before RT | Â | Â | 0.242 |
 Yes | 53 (77.9) | 42 (68.9) |  |
 No | 15 (22.1) | 19 (31.1) |  |
CT cycles before RT | 1 (0–3) | 1 (0–4) | 0.1 |
TI (surgery to CT), days | 8 (5–17) | 7 (5–14) | 0.014 |
TI (surgery to RT), days | 35 (18–100) | 28 (16–120) | <0.001 |
 ≤42 | 45 (66.2) | 51 (83.6) |  |
 43–49 | 13 (19.1) | 3 (4.9) |  |
 50–56 | 4 (5.9) | 1 (1.6) |  |
 57–63 | 0 (0.0) | 1 (1.6) |  |
 ≥64 | 6 (8.8) | 5 (8.2) |  |
Total CT cycles | 3.5 (0–6) | 4 (0–6) | 0.089 |
Grade 3–4 adverse effect | |||
 Hematologic | 32 (47.1) | 16 (26.2) | 0.015 |
 Gastrointestinal | 2 (2.9) | 0 (0) | 0.506 |
 Genitourinary | 4 (5.9) | 2 (3.3) | 0.683 |